QUOFENIX

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug QUOFENIX contains one active pharmaceutical ingredient (API):

1	Delafloxacin UNII N7V53U4U4T - DELAFLOXACIN MEGLUMINE
	Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination.
	Read more about Delafloxacin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QUOFENIX Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
QUOFENIX Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA23		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1809109, 1809110, 1809121, 1809132, 1809143, 1809154, 1809165
ES	Centro de información online de medicamentos de la AEMPS	1191393001, 1191393002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	439060
FR	Base de données publique des médicaments	62560479, 69148567
GB	Medicines & Healthcare Products Regulatory Agency	387209, 387215
IE	Health Products Regulatory Authority	89106
IT	Agenzia del Farmaco	048404014, 048404026, 048404038, 048404040, 048404053, 048404065, 048404077
LT	Valstybinė vaistų kontrolės tarnyba	1089137, 1089138, 1089139, 1089140, 1089141, 1089142, 1089143
PL	Rejestru Produktów Leczniczych	100429680, 100429705